340B Program Evolution: Understanding Impact on Payers

ACPE UAN #:  0233-0000-17-025-H04-P

Release Date: March 29, 2017

Expiration Date:  March 29, 2020

Activity Type:    Knowledge-based

Contact Hours:  1.25

Activity Fee:  Member:  $15        Non-Member: $30

Target Audience: Pharmacists who practice in managed care settings.

Activity Overview

Initially intended as a public-sector, safety-net program to provide under- or uninsured patients access to prescription drugs, the 340B drug pricing program has affected many more patients and at a much higher cost than expected. In fact, in 2011, the Government Accountability Office investigated several 340B organizations and found that many had made their most profits from patients with private insurance and Medicare. Furthermore, it is estimated that roughly half of outpatient drug spending under Medicare Part B comes from hospitals participating in 340B programs, primarily in specialty pharmaceuticals and biologics used to treat severe diseases such as cancer, rheumatoid arthritis and macular degeneration.  The 340B program has evolved into a source of major pro¬ t for some covered entities. This session will explore the evolution of 340B programs, their impact on payers, and strategies payers can use to help address some challenges.

Learning Objectives:  

At the completion of this activity, participants should be able to:

1. Explain how the 340B program has evolved over the years to what it is today.

2. Summarize the impact of the 340B program on providers, manufacturers, and payers.

3. Discuss strategies payers can adopt to address challenges faced due to the 340B program.

4. Describe the fate of the Health Resources and Services Administration (HRSA) proposed rule and potential future changes to the 340B program. 

Schedule of Educational Activity

This activity consists of an audio recording, pre-test assessment questions (not required to pass or continue), post-test questions (required to pass with a score of 70% or higher) and a specific activity evaluation. 

CPE Requirements:   

Participants should claim continuing pharmacy education (CPE) credit for this home study activity only if they have not claimed credit for the live activity presented at the AMCP Annual Meeting 2017.   CPE credit will be processed through the AMCP Learn portal and reported directly to CPE Monitor.  Please allow 72 hours for processing and posting in your NABP account. 

To receive credit for an online activity you must:

  • Review the full content of the activity.
  • Successfully complete the post-test (required to pass with a score of 70% or higher, it may be taken a maximum of three times).
  • Complete a specific activity evaluation.

System Technical Requirements/Viewing Requirements: System Requirements Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites.  View the minimum technical and system requirements for continuing education online learning activities.

As an accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of continuing pharmacy education (CPE) activities.  It is AMCP’s intent that all CPE activities be independent, objective, balanced, evidence-based and free of any commercial bias.

Moderator:

Neil Minkoff, MD | Chief Medical Officer | EmpiraMed, Inc. |  Sudbury, Massachusetts

Credit Information

Activity Number Credit Amount Accreditation Period
ACPE UAN #0233-0000-17-025-H04-P 1.25 Contact Hours March 29, 2017 - March 29, 2020